AIDS and Behavior · 2020 · 82 citations · 33 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyComparative Effectiveness ResearchOutcomes ResearchAntiretroviral TherapyAntiviral TherapyDrug Efficacy AssessmentEfficacy EvaluationTreatment DurationTreatment EffectivenessEfficacy ComparisonHealth Status InstrumentsLong-acting Antiretroviral TherapyOral TreatmentPatient-reported Outcome MeasurementPatient-reported Outcome MonitoringSatisfactionTreatment Satisfaction
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (HIVTSQ) and acceptance (ACCEPT general domain), health status (SF-12), injection tolerability/acceptance (PIN), and treatment preference. In pooled analyses, LA-treated patients (n = 591) demonstrated greater mean improvements from baseline than the CAR group (n = 591) in treatment satisfaction (Week 44, + 3.9 vs. +0.5 HIVTSQs-points; p < 0.001) and acceptance (Week 48, +8.8 vs. +2.0 ACCEPT-points; p < 0.001). The acceptability of injection site reactions (PIN) significantly improved from week 5 (2.10 points) to week 48 (1.62 points; p < 0.001). In both studies, ≥ 97% of LA group participants with recorded data preferred LA treatment compared with prior oral therapy. These results further support the potential of a monthly injectable option for people living with HIV seeking an alternative to daily oral treatment.
33
The MOS 36-ltem Short-Form Health Survey (SF-36)
John E. Ware, Cathy D. Sherbourne · Medical Care · 1992 · 29.8K citations
A 12-Item Short-Form Health Survey
John E. Ware, Mark Kosinski, Susan Keller · Medical Care · 1996 · 17.1K citations
New Multiple Sclerosis Phenotypic Classification
Fred Lublin · European Neurology · 2014 · 4.3K citations